Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Childhood ADHD and comorbid oppositional defiant disorder (ODD) and conduct disorder (CD) are
considered risk factors for subsequent substance abuse, and youth with both ADHD and ODD/CD
are at greatest risk.
However, the effects of treatment of ADHD with stimulant medications such as methylphenidate
(MPH) and mixed amphetamine salts (MAS) on risk for substance abuse are poorly understood.
The study team propose to use fMRI to study the effects of extended release mixed amphetamine
salts (MAS-XR) in drug-naïve youth 7-12 years at low risk (i.e., ADHD only) and high risk
(i.e., ADHD + ODD/CD) for substance abuse on the brain reward system, to better understand
the potential impact of these medications on an aspect of brain functioning which is thought
to underlie vulnerability to substance abuse.
Phase:
Phase 4
Details
Lead Sponsor:
Jeffrey Newcorn
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Adderall Amphetamine Central Nervous System Stimulants Dextroamphetamine